Search all medical codes

Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]) qualitative or semiquantitative; severe acute r...

CPT4 code

Name of the Procedure:

Infectious Agent Antigen Detection by Immunoassay Technique (e.g., Enzyme Immunoassay [EIA], Enzyme-Linked Immunosorbent Assay [ELISA], Fluorescence Immunoassay [FIA], Immunochemiluminometric Assay [IMCA]), Qualitative or Semiquantitative; Severe Acute Respiratory Syndromes

Summary

This procedure involves using immunoassay techniques, such as EIA, ELISA, FIA, or IMCA, to detect specific antigens related to infectious agents that cause severe acute respiratory syndromes. The test can provide qualitative or semiquantitative results to help diagnose infections.

Purpose

The procedure aims to identify specific antigens from pathogens that cause severe acute respiratory conditions. This detection is crucial for diagnosing diseases like SARS and other severe respiratory infections. The goals are to confirm the presence of the infectious agent and guide appropriate treatment.

Indications

  • Patients with symptoms such as high fever, cough, difficulty breathing, and other signs of severe respiratory infection.
  • Individuals who have been exposed to known outbreaks of severe acute respiratory syndromes.
  • Patients requiring confirmation of a suspected pathogen based on initial clinical assessments.

Preparation

  • Generally, no special preparation like fasting is required.
  • Patients should inform their healthcare provider about any medications they are taking.
  • A pre-procedure consultation might include a review of medical history and recent symptoms.

Procedure Description

  1. A blood sample, nasal swab, or another appropriate specimen is collected from the patient.
  2. The sample is processed and prepared for analysis.
  3. The immunoassay technique (EIA, ELISA, FIA, or IMCA) is used to detect specific antigens in the sample.
    • EIA and ELISA involve enzyme-labeled antibodies that produce a measurable signal when the antigen is present.
    • FIA uses fluorescent-labeled antibodies to detect the antigen.
    • IMCA involves chemiluminescent reactions to identify the antigen.
  4. The results are analyzed to determine the presence of the infectious agent.

Duration

The entire procedure, from sample collection to obtaining results, typically takes a few hours to a day.

Setting

The procedure is usually performed in a laboratory setting. Specimen collection can take place in a hospital, clinic, or outpatient setting.

Personnel

  • Laboratory technicians or medical technologists for analyzing samples.
  • Nurses or medical assistants may collect specimens.
  • Physicians or specialists for interpreting results.

Risks and Complications

  • Minor discomfort or bruising at the sample collection site.
  • Very rare risk of infection at the puncture site.
  • False positive or negative results, necessitating further testing or clinical correlation.

Benefits

  • Accurate and rapid detection of pathogens causing severe acute respiratory syndromes.
  • Early diagnosis facilitating timely and appropriate treatment.
  • Helps in tracking and managing infectious disease outbreaks.

Recovery

  • No specific recovery period required; patients can usually resume normal activities immediately.
  • Follow any specific instructions provided by the healthcare provider.
  • There may be a follow-up appointment to discuss results and next steps.

Alternatives

  • PCR (Polymerase Chain Reaction) tests for genetic material of the pathogen.
  • Rapid antigen tests for immediate diagnosis.
  • Clinical evaluation and imaging studies for supportive diagnosis.
  • Each alternative has varying sensitivity, specificity, and timeframes for results.

Patient Experience

  • Mild discomfort during sample collection, e.g., a nasal swab or blood draw.
  • Minimal to no pain or side effects post-procedure.
  • Anxiety while waiting for results, mitigated through providing comprehensive pre-procedure information and support.

Note: Patients should discuss all concerns and questions with their healthcare provider to ensure they are adequately informed about the procedure and its implications.

Medical Policies and Guidelines for Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [eia], enzyme-linked immunosorbent assay [elisa], fluorescence immunoassay [fia], immunochemiluminometric assay [imca]) qualitative or semiquantitative; severe acute r...

Related policies from health plans

Similar Codes